NEW YORK (GenomeWeb News) - Oxford Genome Sciences today said it has received an equity placement from three investors, including previous investors South East Growth Fund and Oxford Capital Partners, and first-time investor Catapult Growth Fund.
A company spokesperson declined to disclose the amount of the financing.
OGeS develops disease-related proteins for use in cancer diagnostics and therapeutics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.